Companies › Shanghai Jiaolian Drug Research and Development
3 active drug programs in 6 registered trials: 5 Phase 2, 1 Phase 1; Neurology, Genitourinary, Immunology, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| B007 Anti-CD20 monoclonal antibody | CD20 | Phase 2 | Generalized Myasthenia Gravis; Pemphigus; Primary Membranous Nephropathy | Dec 2026 |
| B013 | – | Phase 2 | Platinum-resistant Recurrent Ovarian Cancer | Dec 2026 |
| B001 | – | Phase 2 | Neuromyelitis Optica Spectrum Disorders | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06447597 | B007 | Phase 2 | Generalized Myasthenia Gravis | Neurology | Dec 2026 |
| NCT05668403 | B007 | Phase 1 | Primary Membranous Nephropathy | Genitourinary | Dec 2026 |
| NCT06454357 | B007 | Phase 2 | Pemphigus | Immunology | Dec 2026 |
| NCT06470191 | B007 | Phase 2 | Primary Membranous Nephropathy | Genitourinary | Dec 2026 |
| NCT06434610 | B013 | Phase 2 | Platinum-resistant Recurrent Ovarian Cancer | Oncology | Dec 2026 |
| NCT06413654 | B001 | Phase 2 | Neuromyelitis Optica Spectrum Disorders | Neurology | Oct 2027 |
Arctic Therapeutics Woolsey Pharmaceuticals Kissei Pharmaceutical Sundance Biosciences Teikoku Pharma USA
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.